This experiment addresses the critical aging knowledge gap: "What determines selective neuronal vulnerability to aging?" (ranked #1 in Aging Knowledge Gaps with 31 points). Different neuronal populations age at dramatically different rates — dopaminergic neurons in the substantia nigra, cholinergic neurons in the basal forebrain, and entorhinal cortex layer II neurons are disproportionately vulnerable, while neighboring cells survive into the tenth decade.
Related: Aging Knowledge Gaps | Selective Neuronal Vulnerability | Alzheimer's Disease | Parkinson's Disease
Why do specific neuronal subtypes fail with age while their neighbors remain intact? Is vulnerability determined by metabolic load, calcium handling capacity, axonal length, neurotransmitter type, protein turnover rates, or some combination? Solving this would explain why Parkinson's specifically targets dopaminergic neurons while Alzheimer's preferentially damages cholinergic neurons and cortical pyramids.
Selective neuronal vulnerability is one of the most consistent yet unexplained phenomena in neuroscience. The substantia nigra pars compacta (SNc) dopaminergic neurons are lost in Parkinson's disease, yet ventral tegmental area (VTA) dopaminergic neurons are relatively spared. Similarly, layer II entorhinal cortex neurons degenerate early in Alzheimer's disease while adjacent layer III neurons survive. [@mattson2006]
Proposed mechanisms include:
Approach: Single-nucleus multi-omics (snRNA-seq + snATAC-seq + proteomics) across brain regions at multiple ages.
| Brain Region | Neuron Type | Vulnerability | N |
|---|---|---|---|
| Substantia nigra | Dopaminergic (SNc) | High | 30 |
| Ventral tegmental area | Dopaminergic (VTA) | Low | 30 |
| Entorhinal cortex | Layer II stellate | High | 30 |
| Entorhinal cortex | Layer III pyramidal | Low | 30 |
| Basal forebrain | Cholinergic (NbM) | High | 25 |
| Basal forebrain | GABAergic | Low | 25 |
| Hippocampus | CA1 pyramidal | Moderate | 30 |
| Hippocampus | CA2/CA3 pyramidal | Low | 30 |
| Motor cortex | Layer V pyramidal | Low | 30 |
| 眼眶额叶皮层 | Layer V pyramidal | Low | 30 |
Key measurements per neuron type:
Approach: Isogenic iPSC-derived neurons from vulnerable and resilient types, with perturbations.
| Cell Type | Baseline | Perturbation | Readout |
|---|---|---|---|
| SNc dopaminergic | Age-matched VTA | Reduced Complex I | Viability, ROS, mitophagy |
| Layer II entorhinal | Layer III cortical | Elevated calcium influx | Tau phosphorylation, synapse loss |
| Basal forebrain cholinergic | GABAergic | BDNF withdrawal | Survival, function |
Approach: Develop and validate cell-type-specific reporters for:
Validate these in mouse models, then test in postmortem human brain tissue.
| Dimension | Score | Rationale |
|---|---|---|
| Mechanistic Impact | 10/10 | Would fundamentally explain why specific diseases target specific neurons |
| Cure Proximity | 8/10 | Revealing vulnerability mechanisms directly suggests protective strategies |
| Feasibility | 7/10 | Multi-omics and iPSC technology are mature; human tissue access is limiting |
| Cost Efficiency | 7/10 | Atlas approach generates broad value across neurodegenerative diseases |
| Timeline | 8/10 | 4-year study with phased deliverables |
| Cross-Disease Value | 10/10 | Directly applicable to AD, PD, ALS, HD, and normal aging |
| Biomarker Enablement | 8/10 | Vulnerability reporters could serve as patient stratification biomarkers |
| Novelty | 9/10 | First comprehensive comparative atlas across vulnerable vs. resilient human neurons |
Overall Score: 67/90 — High priority, high impact, feasible with current technology.
| Component | Cost |
|---|---|
| Postmortem brain collection + multi-omics | $2.8M |
| iPSC generation and differentiation | $1.2M |
| CRISPR screens + validation | $800K |
| Reporter development and validation | $600K |
| Personnel (4 FTE + PI) | $2.5M |
| Data analysis and computation | $400K |
| Total | $8.3M |